- Home
- COGT vs CRF Comparison
COGT vs CRF Comparison
Compare COGT & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- CRF
- Stock Information
- Founded
- COGT 2014
- CRF 1973
- Country
- COGT United States
- CRF United States
- Employees
- COGT N/A
- CRF N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- CRF Finance/Investors Services
- Sector
- COGT Health Care
- CRF Finance
- Exchange
- COGT Nasdaq
- CRF Nasdaq
- Market Cap
- COGT 1.1B
- CRF 953.9M
- IPO Year
- COGT 2018
- CRF N/A
- Fundamental
- Price
- COGT $16.19
- CRF $8.19
- Analyst Decision
- COGT Strong Buy
- CRF
- Analyst Count
- COGT 11
- CRF 0
- Target Price
- COGT $21.20
- CRF N/A
- AVG Volume (30 Days)
- COGT 1.9M
- CRF 1.1M
- Earning Date
- COGT 11-11-2025
- CRF 01-01-0001
- Dividend Yield
- COGT N/A
- CRF 18.10%
- EPS Growth
- COGT N/A
- CRF N/A
- EPS
- COGT N/A
- CRF 1.40
- Revenue
- COGT N/A
- CRF $11,461,786.00
- Revenue This Year
- COGT N/A
- CRF N/A
- Revenue Next Year
- COGT N/A
- CRF N/A
- P/E Ratio
- COGT N/A
- CRF $5.38
- Revenue Growth
- COGT N/A
- CRF 6.53
- 52 Week Low
- COGT $3.72
- CRF $5.70
- 52 Week High
- COGT $16.46
- CRF $9.56
- Technical
- Relative Strength Index (RSI)
- COGT 74.84
- CRF 69.69
- Support Level
- COGT $15.26
- CRF $8.07
- Resistance Level
- COGT $16.22
- CRF $8.14
- Average True Range (ATR)
- COGT 0.71
- CRF 0.06
- MACD
- COGT 0.21
- CRF 0.02
- Stochastic Oscillator
- COGT 92.27
- CRF 82.89
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.